{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:45:49Z","timestamp":1793097949541,"version":"4.5.0"},"reference-count":244,"publisher":"Centers for Disease Control MMWR Office","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr6909a1","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T16:18:21Z","timestamp":1600964301000},"page":"1-41","source":"Crossref","is-referenced-by-count":292,"title":["Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020"],"prefix":"10.15585","volume":"69","author":[{"given":"Sarah A.","family":"Mbaeyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Bozio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorry G.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"MacNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R2","first-page":"794","article-title":"Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine.","volume":"56","author":"Committee on Immunization Practices","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R3","first-page":"1265","article-title":"Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2\u201310 years at increased risk for invasive meningococcal disease.","volume":"56","author":"CDC","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R4","first-page":"1042","article-title":"Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R5","first-page":"273","article-title":"Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use\u2014Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R6","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R7","first-page":"1391","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R8","first-page":"52","article-title":"Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R9","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R10","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R11","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.15585\/mmwr.mm6543a3","article-title":"Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons\u2014Advisory Committee on Immunization Practices, 2016.","volume":"65","author":"MacNeil","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine\u2014Advisory Committee on Immunization Practices, 2016.","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R14","first-page":"567","article-title":"Notice to readers: limited supply of meningococcal conjugate vaccine, recommendation to defer vaccination of persons aged 11\u201312 years.","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R15","unstructured":"Food and Drug Administration. Summary Basis for Regulatory Action\u2014Trumenba. Silver Spring, MD: Food and Drug Administration; October 19, 2014. https:\/\/wayback.archive-it.org\/7993\/20190425012126\/https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424125.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R16","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R17","first-page":"327","article-title":"New framework (GRADE) for development of evidence-based recommendations by the Advisory Committee on Immunization Practices.","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.15585\/mmwr.mm6745a4","article-title":"Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices.","volume":"67","author":"Lee","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R19","unstructured":"Bozio C. Evidence to recommendations Framework (EtR) and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): serogroup B meningococcal (MenB) vaccine booster doses for persons at increased risk for serogroup B meningococcal disease. Presented at the Advisory Committee on Immunization Practices meeting. Atlanta, GA; February 28, 2019. https:\/\/stacks.cdc.gov\/view\/cdc\/78096"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R20","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R21","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R22","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae.","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease\u2014United States, 1996\u20132015.","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis.","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R26","unstructured":"CDC. Enhanced meningococcal disease surveillance reports, 2015\u20132017. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html#enhanced-reports2019"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/cid\/ciy548","article-title":"Epidemiology of meningococcal disease outbreaks in the United States, 2009\u20132013.","volume":"68","author":"Mbaeyi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40471-018-0170-z","article-title":"A review of global epidemiology and response to meningococcal disease outbreaks among men who have sex with men, 2001\u20132018.","volume":"5","author":"Oliver","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018.","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/0140-6736(91)91112-8","article-title":"Influenza A and meningococcal disease.","volume":"338","author":"Cartwright","year":"1991","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00006454-199710000-00015","article-title":"Tobacco smoke as a risk factor for meningococcal disease.","volume":"16","author":"Fischer","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/S0950268800057733","article-title":"Smoking, the environment and meningococcal disease: a case control study.","volume":"112","author":"Stanwell-Smith","year":"1994","journal-title":"Epidemiol Infect"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7326\/0003-4819-123-12-199512150-00007","article-title":"Sporadic meningococcal disease in adults: results of a 5-year population-based study.","volume":"123","author":"Stephens","year":"1995","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R34","first-page":"139","article-title":"Risk factors for meningococcal disease: a case control study in south west England.","volume":"10","author":"Stuart","year":"1988","journal-title":"Community Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies.","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2249.1991.tb06209.x","article-title":"Complement deficiencies and meningococcal disease.","volume":"86","author":"Densen","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1086\/345527","article-title":"Indications for the immunological evaluation of patients with meningitis.","volume":"36","author":"Overturf","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R38","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1699-0463.1990.tb05008.x","article-title":"Inherited complement deficiency states: implications for immunity and immunological disease.","volume":"98","author":"Sj\u00f6holm","year":"1990","journal-title":"APMIS"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R39","unstructured":"Ultomiris (ravulizumab-cwvz). Package insert. Boston, MA: Alexion Pharmaceuticals; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761108s000lbl.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R40","unstructured":"Soliris (eculizumab). Package insert. Boston, MA: Alexion Pharmaceuticals; 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R41","unstructured":"Food and Drug Administration. Alexion briefing information for the November 18, 2014, meeting of the Drug Safety and Risk Management Advisory Committee. Silver Spring, MD: Food and Drug Administration; 2014."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine.","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jinf.2001.0904","article-title":"Risk of infection and death among post-splenectomy patients.","volume":"43","author":"Bisharat","year":"2001","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0039-6109(16)42339-X","article-title":"Postsplenectomy infection.","volume":"61","author":"Francke","year":"1981","journal-title":"Surg Clin North Am"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R45","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/bjs.1800780904","article-title":"Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.","volume":"78","author":"Holdsworth","year":"1991","journal-title":"Br J Surg"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R46","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/QAD.0b013e32833a2520","article-title":"Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R47","doi-asserted-by":"publisher","first-page":"ofw226","DOI":"10.1093\/ofid\/ofw226","article-title":"Meningococcal disease in patients with human immunodeficiency virus infection: a review of cases reported through active surveillance in the United States, 2000\u20132008.","volume":"3","author":"Harris","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV.","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12916-015-0538-6","article-title":"Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study.","volume":"13","author":"Simmons","year":"2015","journal-title":"BMC Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R50","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Sporadic meningococcal disease in adults: results of a 5-year population-based study.","volume":"123","author":"Stephens","year":"1995","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R51","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1128\/JCM.43.9.4811-4814.2005","article-title":"Assessing the risk of laboratory-acquired meningococcal disease.","volume":"43","author":"Sejvar","year":"2005","journal-title":"J Clin Microbiol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R52","unstructured":"CDC. Guidance for the evaluation and public health management of suspected outbreaks of meningococcal disease. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https:\/\/www.cdc.gov\/meningococcal\/downloads\/meningococcal-outbreak-guidance.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R53","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data.","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R54","first-page":"179","article-title":"Epidemic meningitis control in countries in the African meningitis belt, 2018.","volume":"94","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R55","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jama.286.6.688","article-title":"Risk factors for meningococcal disease in college students.","volume":"286","author":"Bruce","year":"2001","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R56","doi-asserted-by":"publisher","first-page":"e20182130","DOI":"10.1542\/peds.2018-2130","article-title":"Meningococcal disease among college-aged young adults: 2014\u20132016.","volume":"143","author":"Mbaeyi","year":"2019","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R57","unstructured":"Weil LM, Blain A, Soeters HM, Mbaeyi SA, Hariri S, McNamara L. Characterizing potential risk factors for serogroup B meningococcal disease among undergraduate college students\u2014United States, 2014\u20132017 [Abstract]. Presented at the Council of State and Territorial Epidemiologists annual conference, Raleigh, NC; June 2\u20136, 2019."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R58","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1086\/344273","article-title":"Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964\u20131998.","volume":"35","author":"Brundage","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R59","unstructured":"Brundage JF, Zollinger WD, Vedros NA. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros NA, ed. Evolution of meningococcal disease (vol. 1). Boca Raton, FL: CRC Press; 1987:6\u201323."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R60","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/cid\/cix438","article-title":"Increased risk for meningococcal disease among men who have sex with men in the United States, 2012\u20132015.","volume":"65","author":"Folaranmi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents.","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R62","unstructured":"Council of State and Territorial Epidemiologists. Revision of the national surveillance case definition for meningococcal disease. Atlanta, GA: Council of State and Territorial Epidemiologists; 2014. https:\/\/cdn.ymaws.com\/www.cste.org\/resource\/resmgr\/2014PS\/14_ID_06upd.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R63","unstructured":"Roush SB, McGee L, Cassiday P, Laboratory support for surveillance of vaccine-preventable diseases [Chapter 22]. In: Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt22-lab-support.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R64","unstructured":"American Academy of Pediatrics. Meningococcal infections [Section 3]. In: Red Book: 2018\u20132021: report of the committee on infectious diseases. Itasca, IL: American Academy of Pediatrics; 2018."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R65","unstructured":"MacNeil J, Patton M. Meningococcal disease [Chapter 8]. In: Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt08-mening.html"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R66","unstructured":"Menactra. Package insert. Swiftwater, PA: Sanofi Pasteur; 2018. https:\/\/www.fda.gov\/media\/75619\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R67","unstructured":"Menveo. Package insert. Sovicille, Italy: GlaxoSmithKline Vaccines; 2019. https:\/\/www.fda.gov\/media\/78514\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R68","unstructured":"MenQuadfi. Package insert. Swiftwater, PA: Sanofi Pasteur; 2020. https:\/\/www.fda.gov\/media\/137306\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R69","unstructured":"Trumenba. Package insert. Philadelphia, PA: Pfizer; 2018. https:\/\/www.fda.gov\/media\/89936\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R70","unstructured":"Bexsero. Package insert. Sovicille, Italy: GlaxoSmithKline Vaccines; 2018. https:\/\/www.fda.gov\/media\/90996\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R71","unstructured":"Menomune\u2013A\/C\/Y\/W-135. Package insert. Swiftwater, PA: Sanofi Pasteur; 2016. https:\/\/www.fda.gov\/media\/83562\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R72","unstructured":"MenHibrix. Package insert. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2012. https:\/\/www.fda.gov\/media\/83688\/download"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R73","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R74","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R75","doi-asserted-by":"publisher","first-page":"e00036-18","DOI":"10.1128\/mBio.00036-18","article-title":"Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine.","volume":"9","author":"McNeil","year":"2018","journal-title":"MBio"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R76","doi-asserted-by":"publisher","first-page":"e00261-17","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States.","volume":"2","author":"Rajam","year":"2017","journal-title":"MSphere"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R77","unstructured":"Food and Drug Administration. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Silver Spring, MD: Food and Drug Administration; 2011. https:\/\/wayback.archive-it.org\/7993\/20170113080442\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM248586.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R78","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide.","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R79","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero\u00ae antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation.","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R80","unstructured":"ClinicalTrials.gov. Study of a tetravalent meningococcal diphtheria toxoid conjugate vaccine in toddlers 9 to 18 months of age (NCT00643916); 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00643916"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R81","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R82","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial.","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R83","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R84","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R85","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7883\/yoken.JJID.2017.277","article-title":"A safety and immunogenicity study of a single dose of a meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MEN-ACWY-D) in healthy Japanese participants.","volume":"71","author":"Fukushima","year":"2018","journal-title":"Jpn J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R86","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-diphtheria toxoid conjugate vaccine in healthy individuals 10\u201325 years of age.","volume":"3","author":"Halperin","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R88","doi-asserted-by":"publisher","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age.","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R89","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R90","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R91","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1128\/CVI.00260-12","article-title":"Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.","volume":"19","author":"Khalil","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R92","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2016.02.010","article-title":"Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea.","volume":"45","author":"Kim","year":"2016","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R93","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4161\/hv.1.6.2301","article-title":"Safety and immunogenicity of a meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.","volume":"1","author":"Lagos","year":"2005","journal-title":"Hum Vaccin"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R94","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/INF.0000000000001124","article-title":"A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents.","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R95","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1155\/2014\/237560","article-title":"Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children.","volume":"25","author":"Noya","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R96","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R97","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/01.inf.0000243215.46312.4a","article-title":"Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.","volume":"25","author":"Pichichero","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R98","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","article-title":"Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies.","volume":"31","author":"Pina","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R99","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R100","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1542\/peds.2009-2336","article-title":"Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel.","volume":"125","author":"Reisinger","year":"2010","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R101","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1542\/peds.2014-4199","article-title":"Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines.","volume":"136","author":"Schilling","year":"2015","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R102","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.vaccine.2010.11.057","article-title":"Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.","volume":"29","author":"Weston","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R103","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1097\/INF.0b013e31822d28df","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and\/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.","volume":"30","author":"Wheeler","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R104","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s13312-014-0435-7","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): a multicenter, open-label, non-randomized, phase III clinical trial.","volume":"51","author":"Yadav","year":"2014","journal-title":"Indian Pediatr"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R105","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1016\/j.vaccine.2016.09.003","article-title":"Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.","volume":"34","author":"Robertson","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R106","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.vaccine.2019.01.008","article-title":"Persistence of bactericidal antibodies 4\u202fyears after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).","volume":"37","author":"Robertson","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R107","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.vaccine.2009.10.050","article-title":"MCV vaccination in the presence of vaccine-associated Guillain-Barr\u00e9 Syndrome risk: a decision analysis approach.","volume":"28","author":"Cho","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R108","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination.","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R109","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R110","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/pds.3353","article-title":"No risk of Guillain-Barr\u00e9 syndrome found after meningococcal conjugate vaccination in two large cohort studies.","volume":"21","author":"Yih","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R111","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.vaccine.2018.02.107","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.","volume":"36","author":"Hansen","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R112","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1016\/j.vaccine.2017.09.032","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.","volume":"35","author":"Hansen","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R113","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1016\/j.vaccine.2009.06.038","article-title":"Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study.","volume":"27","author":"Jackson","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R114","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/pds.4397","article-title":"Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method.","volume":"27","author":"Li","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R115","unstructured":"ClinicalTrials.gov. Antibody persistence and booster dose response in subjects who received Menactra\u00ae three years earlier in study MTA26 (NCT00700713); 2019. https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00700713?term=NCT00700713&rank=12016"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R116","first-page":"1120","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2014United States, June 2005\u2013September 2006.","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R117","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.","volume":"28","author":"Arguedas","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R118","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2\u201310 years of age.","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R119","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/INF.0000000000000965","article-title":"Immunogenicity and safety of a 3- and 4-dose vaccination series of a meningococcal ACWY conjugate vaccine in infants: results of a phase 3b, randomized, open-label trial.","volume":"35","author":"Block","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R120","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1016\/j.vaccine.2014.07.063","article-title":"Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2\u201318 years in Taiwan: results of an open label study.","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R121","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.4161\/hv.29571","article-title":"Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.","volume":"10","author":"Ilyina","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R123","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/INF.0000000000000931","article-title":"Comparative assessment of a single dose and a 2-dose vaccination series of a quadrivalent meningococcal CRM-conjugate vaccine (MenACWY-CRM) in children 2\u201310 years of age.","volume":"35","author":"Johnston","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R124","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R125","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1016\/j.vaccine.2012.03.080","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R126","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijid.2015.07.003","article-title":"Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.","volume":"38","author":"Lalwani","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R127","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijid.2014.06.008","article-title":"Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.","volume":"28","author":"Lee","year":"2014","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R128","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4161\/hv.27051","article-title":"Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.","volume":"10","author":"Nolan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R129","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.","volume":"14","author":"Stamboulian","year":"2010","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R130","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R131","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R132","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.vaccine.2015.02.049","article-title":"Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R133","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R134","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","article-title":"Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.","volume":"33","author":"Findlow","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1128\/CVI.00436-09","article-title":"Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.","volume":"17","author":"Gasparini","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R136","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000930","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration.","volume":"35","author":"Gasparini","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R137","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R138","doi-asserted-by":"publisher","first-page":"e20162084","DOI":"10.1542\/peds.2016-2084","article-title":"Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds.","volume":"139","author":"Tseng","year":"2017","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R139","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.vaccine.2017.02.030","article-title":"Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo\u00ae) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010\u20132015.","volume":"35","author":"Myers","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R140","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/INF.0000000000001696","article-title":"Safety of quadrivalent meningococcal conjugate vaccine in children 2\u201310 years.","volume":"36","author":"Tartof","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R141","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7774\/cevr.2019.8.2.94","article-title":"One-year antibody persistence and safety of a 4-dose schedule of MenACWY-CRM in healthy infants from South Korea.","volume":"8","author":"Lee","year":"2019","journal-title":"Clin Exp Vaccine Res"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jtm.12164","article-title":"Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R143","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.tmaid.2014.04.011","article-title":"Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study.","volume":"12","author":"Alberer","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R144","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jtm.12180","article-title":"Immunogenicity and safety of concomitant administration of a combined hepatitis A\/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R145","first-page":"1","article-title":"Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents.","volume":"5","author":"Gasparini","year":"2014","journal-title":"J Vaccines Vaccin"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R146","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40121-019-00258-5","article-title":"Immunogenicity of a quadrivalent human papillomavirus vaccine when co-administered with tetanus-reduced diphtheria-acellular pertussis and quadrivalent meningococcal conjugate vaccines in healthy adolescents: results from a randomized, observer-blind, controlled trial.","volume":"8","author":"Miao","year":"2019","journal-title":"Infect Dis Ther"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R147","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1016\/j.vaccine.2019.08.065","article-title":"MenACWY-CRM conjugate vaccine booster dose given 4\u20136\u202fyears after priming: results from a phase IIIb, multicenter, open label study in adolescents and adults.","volume":"37","author":"Tipton","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R148","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.vaccine.2016.11.071","article-title":"A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.","volume":"35","author":"Read","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R149","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.vaccine.2019.10.024","article-title":"Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old.","volume":"38","author":"Becerra-Culqui","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R150","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","article-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study.","volume":"16","author":"\u00c1\u00f1ez","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R151","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","article-title":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.","volume":"38","author":"Chang","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R152","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: a phase III randomized study.","volume":"38","author":"Esteves-Jaramillo","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R153","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a phase II randomized study.","volume":"16","author":"Kirstein","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R154","doi-asserted-by":"crossref","unstructured":"Peterson JH, Pan J, Neveu D, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) administered in adolescents 10\u201317 years of age. Presented at the Infectious Diseases Society of America meeting, Washington, DC; October 2\u20136, 2019.","DOI":"10.1093\/ofid\/ofz360.2400"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R155","doi-asserted-by":"crossref","unstructured":"Simon MWB, Christensen S, Baccarini C, Jordanov E, Dhingra MS. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in healthy meningococcal vaccine-naive children (2\u20139 years). Presented at the Infectious Diseases Society of America meeting, Washington, DC; October 2\u20136, 2019.","DOI":"10.1093\/ofid\/ofz360.2401"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R156","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system.","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R157","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/infdis\/168.1.227","article-title":"Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.","volume":"168","author":"Andreoni","year":"1993","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R158","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02918259","article-title":"Complement deficiency states and meningococcal disease.","volume":"12","author":"Figueroa","year":"1993","journal-title":"Immunol Res"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R159","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","article-title":"Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.","volume":"21","author":"Platonov","year":"2003","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R160","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/infdis\/170.2.449","article-title":"Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency.","volume":"170","author":"Schlesinger","year":"1994","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R161","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R162","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R163","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10096-010-1129-2","article-title":"Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.","volume":"30","author":"Meerveld-Eggink","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R164","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1016\/j.vaccine.2011.03.080","article-title":"Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with \u03b2-thalassemia.","volume":"29","author":"Spoulou","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R165","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.vaccine.2018.02.085","article-title":"Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.","volume":"36","author":"Klein","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R166","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1016\/j.vaccine.2016.06.072","article-title":"Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.","volume":"34","author":"Souza","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R167","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R168","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.","volume":"161","author":"Lujan-Zilbermann","year":"2012","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R169","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R170","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.vaccine.2012.06.069","article-title":"Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults.","volume":"30","author":"Bertolini","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R171","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/INF.0000000000000630","article-title":"Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.","volume":"34","author":"Frota","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R172","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1016\/j.vaccine.2017.10.043","article-title":"Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.","volume":"35","author":"Frota","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R173","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jped.2017.01.003","article-title":"Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus.","volume":"93","author":"Frota","year":"2017","journal-title":"J Pediatr (Rio J)"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R174","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0020-7292(02)00197-2","article-title":"ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995).","volume":"78","author":"American College of Obstetricians and Gynecologists","year":"2002","journal-title":"Int J Gynaecol Obstet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R175","first-page":"1","article-title":"Update on overall prevalence of major birth defects\u2014Atlanta, Georgia, 1978\u20132005.","volume":"57","author":"CDC","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R176","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R177","doi-asserted-by":"publisher","first-page":"478.e1","DOI":"10.1016\/j.ajog.2013.02.027","article-title":"Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System.","volume":"208","author":"Zheteyeva","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R178","doi-asserted-by":"publisher","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine.","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R179","first-page":"e201990","article-title":"Meningococcal disease incidence before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States.","author":"Mbaeyi","year":"2020","journal-title":"JAMA Pediatr"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R180","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15585\/mmwr.mm6733a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2017.","volume":"67","author":"Walker","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R181","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R182","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R183","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R184","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2017.11.040","article-title":"Meningococcal carriage among a university student population \u2014 United States, 2015.","volume":"36","author":"Breakwell","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R185","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/infdis\/jix446","article-title":"Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak\u2014Oregon, 2015\u20132016.","volume":"216","author":"McNamara","year":"2017","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R186","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/cix091","article-title":"Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college\u2014Rhode Island, 2015\u20132016.","volume":"64","author":"Soeters","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R187","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/5584_2014_22","article-title":"Effectiveness of immunoprophylaxis in suppressing carriage of Neisseria meningitidis in the military environment.","volume":"836","author":"Korzeniewski","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R188","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R189","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/infdis\/jix596","article-title":"Limited impact of adolescent meningococcal ACWY vaccination on Neisseria meningitidis serogroup W carriage in university students.","volume":"217","author":"Oldfield","year":"2018","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R190","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/bmj.320.7238.846","article-title":"Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study.","volume":"320","author":"Neal","year":"2000","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R191","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R192","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14760584.2019.1578217","article-title":"Introduction of a second MenB vaccine into Europe\u2014needs and opportunities for public health.","volume":"18","author":"Findlow","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R193","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","article-title":"Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"17","author":"Marshall","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R194","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R195","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults.","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R196","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R197","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine.","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R198","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.vaccine.2018.11.073","article-title":"Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents.","volume":"37","author":"Vesikari","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R199","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents.","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R200","unstructured":"Mbaeyi SA. Serogroup B meningococcal vaccines booster doses: work group interpretation, considerations for policy options, and next steps. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 28, 2019. https:\/\/stacks.cdc.gov\/view\/cdc\/78097"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R201","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group b vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents.","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R202","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/INF.0000000000001742","article-title":"Adverse events following vaccination with bivalent rLP2086 (Trumenba\u00ae): an observational, longitudinal study during a college outbreak and a systematic review.","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R203","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains.","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R204","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","article-title":"Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.","volume":"35","author":"Taha","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R205","doi-asserted-by":"publisher","first-page":"e00121-17","DOI":"10.1128\/CVI.00121-17","article-title":"Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine.","volume":"24","author":"Lujan","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R206","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5414\/CN107777","article-title":"The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies.","volume":"83","author":"Kim","year":"2015","journal-title":"Clin Nephrol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R207","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 glomerulopathy.","volume":"32","author":"Riedl","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R208","unstructured":"European Medicines Agency. Trumenba: EPAR\u2014Public assessment report. Amsterdam, Netherlands: European Medicines Agency; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/trumenba-epar-public-assessment-report_en.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R209","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R210","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial.","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R211","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.vaccine.2016.01.033","article-title":"Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea\u2014a randomised trial.","volume":"34","author":"Lee","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R212","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","article-title":"Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.","volume":"33","author":"Perrett","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R213","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R214","unstructured":"ClinicalTrials.gov. Phase 2, observer-blind, placebo-controlled, randomized, multi-center extension study to evaluate the safety and immunogenicity of a booster dose of a MenABCWY vaccine administered 24 months following the primary series to adolescents and young adults who participated in V102_03 (NCT01992536); 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01992536?term=NCT01992536&rank=1"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R215","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R216","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R217","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/INF.0000000000001896","article-title":"Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study.","volume":"37","author":"Szenborn","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R218","unstructured":"Argante L, Prunas O, Novy P, Modeling of long-term antibody persistence following 4CmenB vaccination in adolescents. Presented at the 15th Congress of the European Meningococcal and Haemophilus Disease Society, Lisbon, Portugal; May 27\u201330, 2019."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R219","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1016\/j.vaccine.2018.10.095","article-title":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.","volume":"36","author":"De Serres","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R220","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/07448481.2017.1312418","article-title":"Safety of a meningococcal group B vaccine used in response to two university outbreaks.","volume":"65","author":"Duffy","year":"2017","journal-title":"J Am Coll Health"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R221","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1016\/j.vaccine.2016.06.025","article-title":"Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: a Canadian Immunization Research Network study.","volume":"34","author":"Langley","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R222","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1514866","article-title":"Immunogenicity of a meningococcal B vaccine during a university outbreak.","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R223","unstructured":"Basta NE, Borrow R. Does 4CMenB vaccine-induced immunity against a meningococcal B outbreak strain persist 20 months after vaccination? [Poster]. Presented at the 22nd International Pathogenic Neisseria Conference, Asilomar, CA; September 23\u201328, 2018."},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R224","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/cid\/cix519","article-title":"Serum bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus.","volume":"65","author":"Lujan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R225","doi-asserted-by":"publisher","first-page":"e00430-16","DOI":"10.1128\/CVI.00430-16","article-title":"Serum bactericidal antibody responses of adults immunized with the MenB-4C vaccine against genetically diverse serogroup B meningococci.","volume":"24","author":"Giuntini","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R226","doi-asserted-by":"publisher","first-page":"e01625-14","DOI":"10.1128\/mBio.01625-14","article-title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.","volume":"5","author":"Costa","year":"2014","journal-title":"MBio"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R227","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/infdis\/jiv081","article-title":"Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine.","volume":"212","author":"Granoff","year":"2015","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R228","doi-asserted-by":"publisher","first-page":"e00393-19","DOI":"10.1128\/mSphere.00393-19","article-title":"Anti-factor H antibody reactivity in young adults vaccinated with a meningococcal serogroup B vaccine containing factor H binding protein.","volume":"4","author":"Sharkey","year":"2019","journal-title":"MSphere"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R229","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.vaccine.2019.07.017","article-title":"Nephrotic syndrome following four-component meningococcal B vaccination: epidemiologic investigation of a surveillance signal.","volume":"37","author":"De Serres","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R230","doi-asserted-by":"publisher","first-page":"e20174250","DOI":"10.1542\/peds.2017-4250","article-title":"Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function.","volume":"142","author":"Martin\u00f3n-Torres","year":"2018","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R231","doi-asserted-by":"publisher","first-page":"e20162452","DOI":"10.1542\/peds.2016-2452","article-title":"Meningococcal B vaccine failure with a penicillin-resistant strain in a young adult on long-term eculizumab.","volume":"140","author":"Parikh","year":"2017","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R232","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.vaccine.2018.03.087","article-title":"A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.","volume":"36","author":"Reher","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R233","unstructured":"Health Canada. Summary safety review\u2014Soliris (eculizumab) and Bexsero\u2014assessing the potential risk of hemolysis and low hemoglobin in patients treated with Soliris and vaccinated with Bexsero. Ottawa, Ontario: Health Canada; 2016. https:\/\/hpr-rps.hres.ca\/reg-content\/summary-safety-review-detail.php?lang=en&linkID=SSR00104"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R234","unstructured":"Alexion Inc. Soliris (eculizumab) product monograph [Canada]. Boston, MA: Alexion Pharmaceuticals; 2018. https:\/\/alexion.com\/Documents\/Canada\/Product-Monograph-Soliris-English-20Aug2018.aspx"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R235","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R236","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England.","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R237","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.15585\/mmwr.mm6933a1","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2019.","volume":"69","author":"Elam-Evans","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R238","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia.","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R239","unstructured":"Meyer SA. Epidemiology of meningococcal disease among college students\u2014United States, 2014\u20132016. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; February 22, 2018. https:\/\/stacks.cdc.gov\/view\/cdc\/59918"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R240","unstructured":"CDC. ACIP shared clinical decision-making recommendations [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/acip-scdm-faqs.html"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R241","unstructured":"Ezeanolue EHK, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R242","unstructured":"ClinicalTrials.gov. A trial to describe the immunogenicity and safety of 2 doses of bivalent rLP2086 (Trumenba) and a pentavalent meningococcal vaccine in healthy subjects \u226510 to <26 years of age (NCT03135834). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03135834?term=MenABCWY&rank=72019"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R243","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr6909a1-202101081550-R244","unstructured":"Meningitis Research Foundation. A global vision for meningitis by 2030 and an action plan to get there. West Sussex, UK: Wilton Park; 2017."}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T23:05:56Z","timestamp":1617491156000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/69\/rr\/rr6909a1.htm?s_cid=rr6909a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":244,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,25]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr6909a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,25]]},"published":{"date-parts":[[2020,9,25]]}}}